Tous Actualités
Suivre
Abonner IsoTis OrthoBiologics

IsoTis OrthoBiologics

IsoTis Reports Interim Results of Vote for Integra Merger

Irvine, California (ots/PRNewswire)

- Conference Calls to Answer Questions About Stockholder Meeting
October 23
IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company,
today announced the interim tabulation results of the special
stockholders meeting held on October 11, 2007 and adjourned to
October 23, 2007.
Prior to October 11, 2007, approximately 2,555,000 shares, 36
percent of the shares entitled to vote, voted for the merger with
Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra")
pursuant to an agreement and plan of merger dated as of August 6,
2007.
The votes "for" the merger represented 93% percent of the total
number of approximately 2,753,000 votes cast prior to October 11,
2007. As announced on October 12, 2007, the number of shares
represented at the meeting was insufficient to establish the quorum
of 3,549,615 shares necessary to approve the proposed merger. The
special stockholders meeting has been adjourned to October 23, 2007
at 7.30 a.m. Pacific time. It will be held at the offices of Latham &
Watkins LLP, 650 Town Center Drive, Suite 2000, Costa Mesa CA.
The vast majority of IsoTis' stockholder base resides outside the
United States of America and includes thousands of Swiss and Dutch
private individuals. Based on the results now available, many of
these shares have not been voted.
The adjournment of the meeting will provide these and other IsoTis
stockholders additional time to vote their shares. It will also allow
their Swiss and Dutch banks and brokers to be more effective
informing these stockholders about the transaction, and to take and
pass on their votes to the US custodian banks. Approximately 999,000
additional shares voting in favor of the proposed transaction are
necessary to approve the Integra acquisition.
IsoTis also announced that it will host two conference calls
on October 17, where investors can ask questions about the special
stockholders meeting in German, French, Dutch or English:
Conference call details
    Date: October 17, 2007
    German / French / English operator
    Time: 16:30-17:30 CET
    Dial In: 00-41-(0)91-610-5609
    Dutch / English operator
    Time: 17:30-18:30 CET
    Dial In: 00-800-4546-4748
The IsoTis Board of Directors continues to believe unanimously
that the interests of IsoTis' stockholders are best served by the
acquisition by Integra, and that there are no feasible alternatives
for the company and the stockholders. If IsoTis is unable to obtain
the vote necessary to approve the proposed transaction, the company
believes it will have to seek bankruptcy protection.
About IsoTis
IsoTis is an orthobiologics company that develops, manufactures
and markets proprietary products for the treatment of musculoskeletal
diseases and disorders. IsoTis' current orthobiologics products are
bone graft substitutes that promote the regeneration of bone and are
used to repair natural, trauma-related and surgically-created defects
common in orthopedic procedures, including spinal fusions. IsoTis'
current commercial business is highlighted by its Accell line of
products, which the company believes represents the next generation
in bone graft substitution.
On August 7, 2007 Integra and IsoTis announced that they have
reached a definitive agreement to create a global orthobiologics
leader. The combination would create a comprehensive orthobiologics
portfolio, one of the largest sales organizations focused on
orthobiologics in the US, and multiple cross-selling opportunities.
The transaction is subject to approval of IsoTis' stockholders, as
well as other closing conditions and approvals. Upon closing, IsoTis
will become a wholly-owned subsidiary of Integra and Integra will be
one of the largest companies in the world focused on advanced
technology in orthobiologics.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including those that refer to
management's plans and expectations for, among other things, future
operations, strategies, prospects, performance and financial
condition and IsoTis' proposed acquisition by Integra. Words such as
"strategy," "expects," "plans," "anticipates," "believes," "may,"
"will," "might," "could," "would," "continues," "estimates,"
"intends," "pursues," "projects," "goals," "targets" or the negative
or other variations thereof and other words of similar meaning are
intended to identify such forward-looking statements. One can also
identify them by the fact that they do not relate strictly to
historical or current facts. Such statements are based on the current
expectations and projections of the management of IsoTis only. Undue
reliance should not be placed on these statements because, by their
nature, they are subject to known and unknown risks and can be
affected by factors that are beyond the control of IsoTis. Actual
results could differ materially from current expectations and
projections. Any forward-looking statements are made pursuant to the
Private Securities Litigation Reform Act of 1995 and, as such, speak
only as of the date made. IsoTis undertakes no obligation to publicly
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
A special stockholder meeting was held on October 11, 2007 to
obtain stockholder approval of the proposed transaction. This meeting
has been adjourned to October 23, 2007. IsoTis has filed with the
Securities and Exchange Commission and distributed to its
stockholders a definitive proxy statement and other relevant
documents in connection with the special stockholder meeting for the
proposed transaction. IsoTis stockholders are urged to read the
definitive proxy statement and other relevant materials because they
contain important information about IsoTis, Integra and the proposed
transaction. Investors may obtain a free copy of these materials and
other documents filed by IsoTis with the Securities and Exchange
Commission at the SEC's website at http://www.sec.gov, at IsoTis'
website at  http://www.isotis.com or by sending a written request to
IsoTis at 2  Goodyear, Irvine, California 92618, Attention: Chief
Financial Officer.
IsoTis and its directors, executive officers and certain other
members of management and employees may be deemed to be participants
in soliciting proxies from its stockholders in favor of the proposed
merger. Information regarding the persons who may, under the rules of
the SEC, be considered to be participants in the solicitation of
IsoTis' stockholders in connection with the proposed transaction is
set forth in IsoTis' definitive proxy statement for its special
meeting. Additional information regarding these individuals and any
interest they have in the proposed transaction is set forth in the
definitive proxy statement on file with the SEC.

Contact:

For information contact: Rob Morocco, CFO, +1-949-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-949-855-7195 or +41-21-620-6011, hans.herklots@isotis.com

Plus de actualités: IsoTis OrthoBiologics
Plus de actualités: IsoTis OrthoBiologics
  • 11.10.2007 – 23:13

    IsoTis Adjourns Special Meeting to October 23, 2007

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders it called to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The special meeting of stockholders was held at ...

  • 19.09.2007 – 14:10

    IsoTis - Integra Merger

    Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...

  • 05.09.2007 – 22:27

    IsoTis Files Definitive Proxy Statement

    Irvine, California (ots/PRNewswire) - - Special Stockholders Meeting to Approve Merger With Integra on October 11, 2007 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") combination. ...